BACKGROUND: The development of prostate tumors has been linked to co-morbid diabetes mellitus (DM) in several studies, potentially through the stimulation of insulin-like growth factor receptor (IGFR). This study evaluates the effect of anti-diabetic medication use on the development of high grade tumors and time to tumor progression compared to non-diabetics. METHODS: This retrospective, nested case control study identified patients with prostate cancer (PCa) from the Kentucky Medicaid Database. Cases were diagnosed with PCa and DM and using at least one of the following antidiabetic medications; sulfonylureas, insulin, metformin or TZDs. Cases were further stratified on their insulin exposure resulting from therapy. Controls were those with PCa without DM or any anti-diabetic medications. RESULTS: The use of metformin or TZDs trended toward decreased odds of high-grade tumors and decreased risk of progression, while sulfonylureas and high-dose insulin tended toward an increased odds of high-grade tumors and increase the risk of progression compared to non-diabetics. CONCLUSIONS: Future studies should be conducted to further evaluate the effects of anti-diabetic medications on tumor grade and time to prostate cancer progression.
BACKGROUND: The development of prostate tumors has been linked to co-morbid diabetes mellitus (DM) in several studies, potentially through the stimulation of insulin-like growth factor receptor (IGFR). This study evaluates the effect of anti-diabetic medication use on the development of high grade tumors and time to tumor progression compared to non-diabetics. METHODS: This retrospective, nested case control study identified patients with prostate cancer (PCa) from the Kentucky Medicaid Database. Cases were diagnosed with PCa and DM and using at least one of the following antidiabetic medications; sulfonylureas, insulin, metformin or TZDs. Cases were further stratified on their insulin exposure resulting from therapy. Controls were those with PCa without DM or any anti-diabetic medications. RESULTS: The use of metformin or TZDs trended toward decreased odds of high-grade tumors and decreased risk of progression, while sulfonylureas and high-dose insulin tended toward an increased odds of high-grade tumors and increase the risk of progression compared to non-diabetics. CONCLUSIONS: Future studies should be conducted to further evaluate the effects of anti-diabetic medications on tumor grade and time to prostate cancer progression.
Authors: A D Raval; D Thakker; A Vyas; M Salkini; S Madhavan; U Sambamoorthi Journal: Prostate Cancer Prostatic Dis Date: 2015-02-10 Impact factor: 5.554
Authors: Sara Gandini; Matteo Puntoni; Brandy M Heckman-Stoddard; Barbara K Dunn; Leslie Ford; Andrea DeCensi; Eva Szabo Journal: Cancer Prev Res (Phila) Date: 2014-07-01
Authors: M R Danzig; S Kotamarti; R A Ghandour; M B Rothberg; B P Dubow; M C Benson; K K Badani; J M McKiernan Journal: Prostate Cancer Prostatic Dis Date: 2014-11-18 Impact factor: 5.554
Authors: R M Joentausta; P M Kujala; T Visakorpi; T L J Tammela; T J Murtola Journal: Prostate Cancer Prostatic Dis Date: 2016-08-09 Impact factor: 5.554
Authors: Malte Rieken; Luis A Kluth; Evanguelos Xylinas; Harun Fajkovic; Andreas Becker; Pierre I Karakiewicz; Michael Herman; Yair Lotan; Christian Seitz; Paul Schramek; Mesut Remzi; Wolfgang Loidl; Karl Pummer; Richard K Lee; Talia Faison; Douglas S Scherr; Alexandra Kautzky-Willer; Alexander Bachmann; Ashutosh Tewari; Shahrokh F Shariat Journal: World J Urol Date: 2013-09-24 Impact factor: 4.226
Authors: Weranja K B Ranasinghe; Shomik Sengupta; Scott Williams; Mike Chang; Arthur Shulkes; Damien M Bolton; Graham Baldwin; Oneel Patel Journal: Cancer Med Date: 2014-01-27 Impact factor: 4.452